As with all vaccines, VERORAB may not protect 100% of people vaccinated.
VERORAB must not be administered via the intravascular route; make sure the needle does not penetrate a blood vessel.
Use with caution if the patient is allergic to polymyxin B, to streptomycin or to neomycin (present in trace amounts in the vaccine) or to any antibiotic of the same group.
As with all injectable vaccines, appropriate medical treatment and supervision must be readily available in case of a rare anaphylactic reaction after vaccine administration.
Serological tests (assay of neutralising antibodies using the RFFIT - Rapid Fluorescent Focus Inhibition Test - method) should be performed regularly, see Table 1 under Dosage & Administration.
When the vaccine is administered to subjects with a known decreased immunity (immunodeficiency), due to a suppressive disease or to a concomitant immunosuppressive treatment, a serological test should be performed 2 to 4 weeks after vaccination, see How to use VERORAB under Dosage & Administration.
VERORAB should be administered with caution to subjects with a decreased platelet level (thrombocytopenia) or clotting disorders, because of the risk of bleeding that may occur during intramuscular administration. Talk to the doctor, pharmacist or nurse before using VERORAB.
Driving and using machines: Post-vaccination dizziness was frequently reported. This can temporarily affect the ability to drive or use machines.